EUNew treatments and approvals
Oral doxecitine and doxribtimine approved in the EU for TK2 deficiency
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
On March 26, 2026, the European Commission approved a medicine containing doxecitine and doxribtimine for TK2 deficiency. The medicine is for patients whose symptoms began at the age of 12 or earlier. It is a powder that is mixed with water and taken by mouth three times a day. Most patients regained at least one skill, such as sitting or standing. The most common side effects are diarrhea, vomiting and abdominal pain.
What does it mean for patients and families?
At the time of approval, there was no other approved medicine for this disease in the EU. The approval was granted under exceptional circumstances; further data are expected. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
Avrupa İlaç Ajansı (EMA) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Thymidine kinase 2 (TK2) deficiency
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.